VVUS der nächste hit in den kommenden 4 wochen - 500 Beiträge pro Seite

[trbdteam]

Vivus hat für das medikament alista die phase III erklommen...das bedeutet eine vermarktung in den nächsten 12 monaten..
da wird sicher sich einer finden, der dieses finanziert bzw. übernimmt..
ich schätze ca. 100 % in nicht allzu lange zeitraum (innerhalb 14-21 Tage)

[franzwerner]

Bin schon geraume Zeit drinnen. Die Phase III ist immer eine kritische klinische Phase einer Entwickling. Nur allzu rasch kann hier auch ein Ende eintreten. Gegen eine satte Übernahme hätte ich nichts einzuwenden.
Noch long.

[franzwerner]

Zahlen auf den ersten Blick o.K. Ein nicht kleiner Teil des Geldes jedoch aus einer Klage. Bin mal gespannt wie der Markt das aufnimmt.

[erkilein]

phase 2 ergebnisse zu TA 1790 heute verkündet, die in etwa gleiche Daten wie viagra aufweisen, aber die eigenen grossen clinischen testerfolge nicht ganz bestätigen, premarket Schwankungen zw. 5,30 und 4,20.

Phase III Alista beginnt erst, eine Vermarktung ist erst in 2007 vorgesehen!

[franzwerner]

VIVUS Announces Results for TA-1790 in Phase 2 Head-to-Head Study with Viagra(R)



MOUNTAIN VIEW, Calif., Feb. 6 /PRNewswire-FirstCall/ -- VIVUS, Inc.(NASDAQ-NMS:VVUS) (Nasdaq: VVUS) today announced data on TA-1790, its oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED). The Phase 2 head-to-head at-home study comparing the onset of action between TA-1790 and Pfizer`s (NYSE: PFE) Viagra (sildenafil) showed comparable results. With each product, subjects had erections sufficient to achieve vaginal penetration on approximately 80 percent of attempts. These successful attempts occurred, on average, within 20 minutes after dosing.

This double-blind, randomized, crossover study in the home setting provides additional data to complement the earlier trial in the clinical setting (the in-clinic RigiScan(R) efficacy trial results announced June 2003). The efficacy demonstrated by TA-1790 in this at-home trial continues to support the rapid absorption and onset of action seen in the earlier in-clinic trial; however, it did not out-perform Viagra as it did in the in-clinic study.

"TA-1790`s onset of action was consistently strong in both the at-home and in-clinic studies," said John Dietrich, Ph.D. vice president of Research and Development for VIVUS. "These data and our belief in the overall safety profile of TA-1790 support our plans to continue the TA-1790 clinical development program. The planned Phase 2 dose ranging clinical trial and routine safety studies evaluating the interaction of TA-1790 with various drugs are expected to demonstrate the differentiating characteristics between TA-1790 and other PDE5 inhibitors on the market. These studies will be initiated in the first half of 2004."

VIVUS plans to present full peer-reviewed data results from this Phase 2 at-home study at the Western Sectional meeting of the American Urological Association (AUA) in August 2004.

"The clinical development of TA-1790 is a high priority for VIVUS," said Leland Wilson, VIVUS` president and CEO. "We remain excited about the potential of the product to fill additional needs in the growing ED market."

In March 2001, VIVUS announced it had licensed TA-1790 from Tanabe Seiyaku Co., Ltd. ("Tanabe"), Japan-based pharmaceutical company. The compound is a fast-acting, highly-selective PDE5 inhibitor for the treatment of erectile dysfunction.


Nun schön langsam kommt die Erntezeit.